MedTrace Logo

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

NCT05121428 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 817

Last updated 2025-07-11

No results posted yet for this study

Summary

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Conditions

  • Opioid-use Disorder
  • Acceptability of Health Care
  • Opioid-Related Disorders

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Cambridge Health Alliance

    lead OTHER

Principal Investigators

  • Zev Schuman-Olivier, MD · Cambridge Health Alliance

  • Joseph Rosansky · Cambridge Health Alliance

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-20
Primary Completion
2025-03-20
Completion
2027-03-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05121428 on ClinicalTrials.gov